The University of Pittsburgh Cancer Institute is joining a consortium of organizations in Europe to develop a completely novel approach to fighting cancer.
The Glioma Actively Personalized Vaccine Consortium, which is supported by a grant from the European Union, is the first initiative aimed at clinically developing biomarker-guided actively personalized vaccines, or APVACs, to treat cancer patients.
According to a release from GmbH and BioNTech AG, the two German companies leading the consortium, the project is designed to create, manufacture and develop APVACs tailored for each patient based on the individual aspects of the patient's tumor and immune system.
"This novel approach marks a fundamental paradigm shift in the therapeutic management of cancer patients, since the approach is suited to provide a truly individualized and targeted drug development at unprecedented speed," Ugur Sahin, chief executive officer of BioNTech AG and vice coordinator of the consortium, said in a statement. "In fact, currently, we are able to provide ready-to-administer personalized drugs within three months, whereas average time from target-to-hit to first in human testing is about 5.5 years."
The consortium is expected to address the high, unmet medical need in glioblastoma ? an aggressive form of brain cancer with poor prognosis ? where there are limited treatments available that have a minimal effect on survival.
For its participation, the University of Pittsburgh Cancer Institute, as well as the other academic partners, will apply the APVACs to their patients in addition to contributing to the project with their own research.
Justine Coyne covers manufacturing and higher education.
Source: http://feeds.bizjournals.com/~r/bizj_pittsburgh/~3/s4iOJHOoDwU/pitts-cancer-institute-joins.html
batman Colorado Shooting News joe paterno British Open MC Chris Colorado shooting suspect Finding Nemo 2
No comments:
Post a Comment